Blood products.

R J Hutchinson

Home/Archive/PubMed

PubMed · 1345491

Blood products.

R J Hutchinson

View original source ↗Export metadata ↓

Abstract

Modern transfusion therapy offers the seriously ill patient an array of blood products, designed to improve oxygen delivery, maintain intravascular volume, suppress infection, and induce hemostasis. Depending on the patient's clinical circumstance, the choice of product may need to incorporate consideration of the state of intravascular volume, history of prior transfusion reactions, the possible existence of serum antibodies directed against the relevant blood component, and the risk of transmission of infectious disease, as well as the relative cost of the blood product chosen. Fortunately, the contemporary blood bank has acquired considerable expertise in preparing safe products and in providing sound guidance for the clinician in their proper use.

Explore related subjects

Blood Component Transfusion Blood Transfusion Child Child, Preschool Humans Infant Infant, Newborn Transfusion Reaction Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R J Hutchinson. 1992. Blood products.. https://pubmed.ncbi.nlm.nih.gov/1345491/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Pulmonary transfusion reactions.

Transfusion reactions remain a common complication of transfusion therapy; reactions affecting the lungs are some of the most serious. Several different mechanisms are responsible for pulmonary transfusion reactions, and most cause adverse effects in addition to lung injury. Fluid overload can lead to pulmonary edema, antibodies reacting with plasma proteins can cause bronchospasm and anaphylaxis, and particulate matter can produce microemboli. These reactions are well understood and usually can be prevented. Transfusions are also associated with acute lung injury and acute respiratory distress syndrome (ARDS), but their etiology is poorly understood and they remain clinically problematic. Neutrophil antibodies cause some of these serious as well as mild pulmonary reactions, but the exact role of leukocyte antibodies in pulmonary reactions remains unclear. Other blood donor, blood component, and transfusion recipient factors likely play a contributing or modulating role in pulmonary transfusion reactions, but prospective studies are needed to better understand their role.

Blood Component Transfusion↗

PubMed2007

Portable microscopic cell counter for the determination of residual leucocytes in blood components.

BACKGROUND AND OBJECTIVES: The accurate determination of residual white blood cell (WBC) in blood components is of considerable clinical importance, and a variety of methods have been devised for the counting of low levels of residual WBC. In this study, we evaluated the performance of microscopic cell counter with microchannel plastic chip (C-reader) with regard to its ability to quantify WBC in WBC-reduced red cell concentrates. MATERIALS AND METHODS: In order to quantify residual WBC with the microscopic cell counter, WBC-reduced red cell concentrate was stained using propidium iodide. Three studies were performed: linearity, precision and correlation compared to those of manual Nageotte chamber counting and automatic flow cytometric methods. RESULTS: Dilution experiments, conducted over a range of 0.7-712 WBC/microl, showed a linearity of r(2) > 0.999, with coefficient of variation values of < or = 15.6% and accuracy of 93.8% over all tested ranges. In comparison with the Nageotte chamber counting and flow cytometric methods, the correlation coefficients were r(2) > 0.995. The detection limit of this method was 0.24 WBC/microl. Total analysis time per sample was approximately 5 min. CONCLUSION: The microscopic cell counter for residual WBC counting was determined to be efficient at the level of currently defined standards, with acceptable precision and accuracy. This method may prove useful for the quality assurance and control of WBC-depleted blood products.

Blood Component Transfusion↗

PubMed2006

[vCJD epidemiology in France].

Variant Creutzfeldt-Jakob disease (vCJD) is the only form of prion diseases linked to bovine spongiform encephalopathy (BSE). The disease was first described in the United-Kingdom (UK) and France is the second affected country with 21 cases. Clinical, genetic and neuropathological features are the same in both countries. Comparison of the total number of cases in France and in the UK, according to dates of onset, shows that, in France, the maximum incidence seems to be five years delayed and that, in the UK, the number of vCJD cases regularly decreases since 1999. Delayed exposure to contaminated beef products in France compared to the UK could explain this temporal gap. Three cases of vCJD after transfusion of labile blood products were observed in the UK. No such of cases were observed in France but three patients developing signs of vCJD in 2004 were blood donors. A total of 42 recipients were identified with 17 recipients still alive.

Blood Component Transfusion↗